Medicine-taking behavior: Implications of suboptimal compliance in Parkinson's disease

被引:72
作者
Grosset, KA
Reid, JL
Grosset, DG
机构
[1] So Gen Hosp, Inst Neurol Sci, Glasgow, Lanark, Scotland
[2] Western Infirm & Associated Hosp, Dept Med & Therapeut, Glasgow, Lanark, Scotland
关键词
Parkinson's disease; drug compliance; clinical consequences;
D O I
10.1002/mds.20525
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Manauernent of Parkinson's disease (PD) depends primarily on oral medication. There are several drug classes and multiple doses and formulations, which make optimizing therapy complex. Variable drug absorption and the short half-life of most antiparkinson treatments, especially levodopa, are a main focus in understanding complications and have encouraged alternative delivery systems to limit fluctuation and dyskinesia at later stages. Comparatively little attention is paid to the way patients take their oral medication. Variable medicine-taking behavior can affect the clinician's understanding of the diagnosis and rate of progression, and further prescription of PD medication. Medicine overuse in later stage PD is well documented and causes psychiatric disturbance and increases motor complications, but evidence of undertreatment and erratic intake is emerging, which is likely to affect motor control and quality of life adversely. Methods of quantifying compliance are compared for accuracy and limitations. Understanding medicine-taking behavior is a first step in optimizing therapy and requires consideration of a patient's personal beliefs about their medicines. Although the benefits of regularizing oral medicine-taking in a practical, achievable way in PD remain untested, Such an approach might prolong and smooth the benefits of oral medication and is worthy of further research. (c) 2005 Movement Disorder Society.
引用
收藏
页码:1397 / 1404
页数:8
相关论文
共 101 条
[1]   Ropinirole for the treatment of early Parkinson's disease [J].
Adler, CH ;
Sethi, KD ;
Hauser, RA ;
Davis, TL ;
Hammerstad, JP ;
Bertoni, J ;
Taylor, RL ;
SanchezRamos, J ;
OBrien, CF .
NEUROLOGY, 1997, 49 (02) :393-399
[2]   DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS [J].
ANDRADE, SE ;
WALKER, AM ;
GOTTLIEB, LK ;
HOLLENBERG, NK ;
TESTA, MA ;
SAPERIA, GM ;
PLATT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1125-1131
[3]  
[Anonymous], 1997, Perceptions of health and illness: Current research and applications
[4]  
[Anonymous], 1979, Compliance in Health Care
[5]   PRIMARY NONCOMPLIANCE WITH PRESCRIBED MEDICATION IN PRIMARY-CARE [J].
BEARDON, PHG ;
MCGILCHRIST, MM ;
MCKENDRICK, AD ;
MCDEVITT, DG ;
MACDONALD, TM .
BRITISH MEDICAL JOURNAL, 1993, 307 (6908) :846-848
[6]   Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies [J].
Bezard, E ;
Brotchie, JM ;
Gross, CE .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) :577-588
[7]   Updated guidelines for the management of Parkinson's disease [J].
Bhatia, K ;
Brooks, DJ ;
Burn, DJ ;
Clarke, CE ;
Grosset, DG ;
MacMahon, DG ;
Playfer, J ;
Schapira, AHV ;
Stewart, D ;
Widliams, AC .
HOSPITAL MEDICINE, 2001, 62 (08) :456-470
[8]   Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study [J].
Brooks, DJ ;
Sagar, H .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (08) :1071-1079
[9]  
BROOKS DJ, 2002, J NEUROL NEUROSUR S1, V72, P10
[10]   Factors influencing compliance with antiepileptic drug regimes [J].
Buck, D ;
Jacoby, A ;
Baker, GA ;
Chadwick, DW .
SEIZURE, 1997, 6 (02) :87-93